Literature DB >> 23975833

Tumor necrosis factor-like weak inducer of apoptosis (TWEAK) promotes glioblastoma cell chemotaxis via Lyn activation.

Harshil D Dhruv1, Timothy G Whitsett, Nathan M Jameson, Falak Patel, Jeffrey A Winkles, Michael E Berens, Nhan L Tran.   

Abstract

The long-term survival of patients with glioblastoma is compromised by the proclivity for local invasion into the surrounding normal brain, escaping surgical resection and contributing to therapeutic resistance. Tumor necrosis factor-like weak inducer of apoptosis (TWEAK), a member of the tumor necrosis factor superfamily, can stimulate glioma cell invasion via binding to fibroblast growth factor-inducible 14 (Fn14) and subsequent activation of the Rho guanosine triphosphatase family member Rac1. Here, we demonstrate that TWEAK acts as a chemotactic factor for glioma cells, a potential process for driving cell invasion into the surrounding brain tissue. TWEAK exposure induced the activation of Src family kinases (SFKs), and pharmacologic suppression of SFK activity inhibited TWEAK-induced chemotactic migration. We employed a multiplexed Luminex assay and identified Lyn as a candidate SFK activated by TWEAK. Depletion of Lyn suppressed TWEAK-induced chemotaxis and Rac1 activity. Furthermore, Lyn gene expression levels increase with primary glioma tumor grade and inversely correlate with patient survival. These results show that TWEAK-induced glioma cell chemotaxis is dependent upon Lyn kinase function and, thus, provides opportunities for therapeutic targeting of this deadly disease.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23975833      PMCID: PMC3871937          DOI: 10.1093/carcin/bgt289

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  46 in total

1.  Role of Rac in controlling the actin cytoskeleton and chemotaxis in motile cells.

Authors:  C Y Chung; S Lee; C Briscoe; C Ellsworth; R A Firtel
Journal:  Proc Natl Acad Sci U S A       Date:  2000-05-09       Impact factor: 11.205

2.  TRANCE, a TNF family member, activates Akt/PKB through a signaling complex involving TRAF6 and c-Src.

Authors:  B R Wong; D Besser; N Kim; J R Arron; M Vologodskaia; H Hanafusa; Y Choi
Journal:  Mol Cell       Date:  1999-12       Impact factor: 17.970

3.  The tumor necrosis factor-like weak inducer of apoptosis (TWEAK)-fibroblast growth factor-inducible 14 (Fn14) signaling system regulates glioma cell survival via NFkappaB pathway activation and BCL-XL/BCL-W expression.

Authors:  Nhan L Tran; Wendy S McDonough; Benjamin A Savitch; Thomas F Sawyer; Jeffrey A Winkles; Michael E Berens
Journal:  J Biol Chem       Date:  2004-12-16       Impact factor: 5.157

4.  Lyn kinase activity is the predominant cellular SRC kinase activity in glioblastoma tumor cells.

Authors:  Michelle R Stettner; Wenquan Wang; L Burton Nabors; Suman Bharara; Daniel C Flynn; J Robert Grammer; G Yancey Gillespie; Candece L Gladson
Journal:  Cancer Res       Date:  2005-07-01       Impact factor: 12.701

Review 5.  Targeting Src family kinases in anti-cancer therapies: turning promise into triumph.

Authors:  Siyuan Zhang; Dihua Yu
Journal:  Trends Pharmacol Sci       Date:  2011-12-09       Impact factor: 14.819

Review 6.  Molecular mechanisms of glioma cell migration and invasion.

Authors:  Tim Demuth; Michael E Berens
Journal:  J Neurooncol       Date:  2004-11       Impact factor: 4.130

7.  Antibodies to TWEAK receptor inhibit human tumor growth through dual mechanisms.

Authors:  Patricia A Culp; Donghee Choi; Yongke Zhang; Johnny Yin; Pui Seto; Suzanne E Ybarra; Mian Su; Mien Sho; Roxanne Steinle; Melanie H L Wong; Ferdinand Evangelista; Jennifer Grove; Marie Cardenas; Marjorie James; Eric D Hsi; Debra T Chao; David B Powers; Vanitha Ramakrishnan; Robert Dubridge
Journal:  Clin Cancer Res       Date:  2010-01-12       Impact factor: 12.531

Review 8.  Src signaling in cancer invasion.

Authors:  Marcello Guarino
Journal:  J Cell Physiol       Date:  2010-04       Impact factor: 6.384

9.  Cdc42 and the guanine nucleotide exchange factors Ect2 and trio mediate Fn14-induced migration and invasion of glioblastoma cells.

Authors:  Shannon P Fortin; Matthew J Ennis; Cassie A Schumacher; Cassandra R Zylstra-Diegel; Bart O Williams; Julianna T D Ross; Jeffrey A Winkles; Joseph C Loftus; Marc H Symons; Nhan L Tran
Journal:  Mol Cancer Res       Date:  2012-05-09       Impact factor: 5.852

10.  Bead-based profiling of tyrosine kinase phosphorylation identifies SRC as a potential target for glioblastoma therapy.

Authors:  Jinyan Du; Paula Bernasconi; Karl R Clauser; D R Mani; Stephen P Finn; Rameen Beroukhim; Melissa Burns; Bina Julian; Xiao P Peng; Haley Hieronymus; Rebecca L Maglathlin; Timothy A Lewis; Linda M Liau; Phioanh Nghiemphu; Ingo K Mellinghoff; David N Louis; Massimo Loda; Steven A Carr; Andrew L Kung; Todd R Golub
Journal:  Nat Biotechnol       Date:  2008-12-21       Impact factor: 54.908

View more
  9 in total

1.  In Vitro Validation of the Therapeutic Potential of Dendrimer-Based Nanoformulations against Tumor Stem Cells.

Authors:  Nadezhda Knauer; Valeria Arkhipova; Guanzhang Li; Michael Hewera; Ekaterina Pashkina; Phuong-Hien Nguyen; Maria Meschaninova; Vladimir Kozlov; Wei Zhang; Roland S Croner; Anne-Marie Caminade; Jean-Pierre Majoral; Evgeny K Apartsin; Ulf D Kahlert
Journal:  Int J Mol Sci       Date:  2022-05-19       Impact factor: 6.208

Review 2.  The TWEAK receptor Fn14 is a potential cell surface portal for targeted delivery of glioblastoma therapeutics.

Authors:  J G Perez; N L Tran; M G Rosenblum; C S Schneider; N P Connolly; A J Kim; G F Woodworth; J A Winkles
Journal:  Oncogene       Date:  2015-08-24       Impact factor: 9.867

Review 3.  TWEAK/Fn14 Activation Participates in Skin Inflammation.

Authors:  Qilu Liu; Shengxiang Xiao; Yumin Xia
Journal:  Mediators Inflamm       Date:  2017-09-06       Impact factor: 4.711

4.  Identification of aurintricarboxylic acid as a selective inhibitor of the TWEAK-Fn14 signaling pathway in glioblastoma cells.

Authors:  Alison Roos; Harshil D Dhruv; Ian T Mathews; Landon J Inge; Serdar Tuncali; Lauren K Hartman; Donald Chow; Nghia Millard; Holly H Yin; Jean Kloss; Joseph C Loftus; Jeffrey A Winkles; Michael E Berens; Nhan L Tran
Journal:  Oncotarget       Date:  2017-02-14

Review 5.  Regulation of Neuroinflammation: What Role for the Tumor Necrosis Factor-Like Weak Inducer of Apoptosis/Fn14 Pathway?

Authors:  Audrey Boulamery; Sophie Desplat-Jégo
Journal:  Front Immunol       Date:  2017-11-16       Impact factor: 7.561

6.  Immune Characteristics of LYN in Tumor Microenvironment of Gliomas.

Authors:  Chonghua Jiang; Hao Zhang; Wantao Wu; Zeyu Wang; Ziyu Dai; Liyang Zhang; Zhixiong Liu; Quan Cheng
Journal:  Front Cell Dev Biol       Date:  2022-02-02

7.  The TWEAK Receptor Fn14 Is an Src-Inducible Protein and a Positive Regulator of Src-Driven Cell Invasion.

Authors:  Emily Cheng; Timothy G Whitsett; Nhan L Tran; Jeffrey A Winkles
Journal:  Mol Cancer Res       Date:  2014-11-12       Impact factor: 5.852

8.  TWEAK activation of the non-canonical NF-κB signaling pathway differentially regulates melanoma and prostate cancer cell invasion.

Authors:  Cheryl L Armstrong; Rebeca Galisteo; Sharron A N Brown; Jeffrey A Winkles
Journal:  Oncotarget       Date:  2016-12-06

Review 9.  The Role of Rho GTPases in Motility and Invasion of Glioblastoma Cells.

Authors:  Houssam Al-Koussa; Oula El Atat; Leila Jaafar; Hagop Tashjian; Mirvat El-Sibai
Journal:  Anal Cell Pathol (Amst)       Date:  2020-01-31       Impact factor: 2.916

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.